as of 12-04-2025 3:21pm EST
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 162.7M | IPO Year: | 2015 |
| Target Price: | $14.33 | AVG Volume (30 days): | 323.3K |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.53 - $29.98 | Next Earning Date: | 11-05-2025 |
| Revenue: | $351,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
See Remarks
Avg Cost/Share
$17.30
Shares
1,042
Total Value
$18,026.60
Owned After
8,401
SEC Form 4
See Remarks
Avg Cost/Share
$17.30
Shares
76
Total Value
$1,314.80
Owned After
7,623
SEC Form 4
Director
Avg Cost/Share
$17.30
Shares
217
Total Value
$3,754.10
Owned After
11,113
SEC Form 4
See Remarks
Avg Cost/Share
$17.30
Shares
1,257
Total Value
$21,746.10
Owned After
7,527
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Young Teresa L. | MCRB | See Remarks | Nov 15, 2025 | Sell | $17.30 | 1,042 | $18,026.60 | 8,401 | |
| DesRosier Thomas | MCRB | See Remarks | Nov 15, 2025 | Sell | $17.30 | 76 | $1,314.80 | 7,623 | |
| Shaff Eric D. | MCRB | Director | Nov 15, 2025 | Sell | $17.30 | 217 | $3,754.10 | 11,113 | |
| Henn Matthew R. | MCRB | See Remarks | Nov 15, 2025 | Sell | $17.30 | 1,257 | $21,746.10 | 7,527 |
See how MCRB stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "MCRB Seres Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.